IBIS II: A randomised phase III trial of anastrozole for breast cancer prevention in postmenopausal women at high risk.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/569213

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The IBIS II trial builds on the successful IBIS 1 breast cancer (BC) prevention trial in determining whether a chemopreventive strategy towards BC is beneficial. Women who are postmenopausal with an increased risk of BC are randomised to receive either anastrozole (an aromatase inhibitor) or placebo as a daily tablet. Neither the woman nor her clinician know which treatment has been allocated (double blind study). IBIS 2 has the potential to benefit many higher risk women worldwide.

Funded Activity Details

Start Date: 01-01-2009

End Date: 01-01-2013

Funding Scheme: NHMRC Project Grants

Funding Amount: $1,732,559.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Oncology And Carcinogenesis

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Anastrozole | Breast cancer | Clinical trial | Endocrine therapy | Increased risk | Placebo | Postmenopausal | Preventative medicine | Well women | Women's health

Related Links